Skip to main content
Bipolar disorder News Noethen
© Rolf Müller / UKB

News categories: Publication

Large study on the genetics of bipolar disorder

Genetic factors play a major role in the development of bipolar disorder. In an effort to better understand the underlying biology, researchers are constantly studying the genetic makeup of people with bipolar disorder. The Psychiatric Genomics Consortium's Genome-Wide Association Study (GWAS) is the largest of its kind. The study analyzes data from ver 150,000 people of European, East Asian, African-American and Latin American descent. The latest results have now been published in the renowned scientific journal “Nature”.

Either manic episodes with lots of energy or the complete opposite: depression and listlessness - this is what the days of people with bipolar disorder can look like. An estimated 40 to 50 million people worldwide are affected. The illness is associated with a number of negative consequences and risks, including an increased risk of suicide. The causes of bipolar disorder are complex and the biology on which it is based is still largely unexplored. What is clear, however, is that a key risk factor for bipolar disorder is a genetic predisposition. Small variants in a large number of genes are responsible for this predisposition.

“The more we know about the biology behind the disorder and the risk factors, the greater the chance of improved diagnosis and treatment options through precision medicine,” explains Prof. Dr. Andreas Forstner from the Institute of Human Genetics at the UKB and shared last author of the study. He is a member of the Transdisciplinary Research Area (TRA) “Life and Health” at the University of Bonn and also works at the Institute of Neuroscience and Medicine (INM-1) at Forschungszentrum Jülich.

The study compared the genes of more than 2.9 million participants, including over 150,000 people with bipolar disorder. The idea behind this is that many people with bipolar disorder have the same genetic variants that are partly responsible for the illness.

New responsible genes discovered

In total, the study identified 298 regions of the genome in which genetic variants increase the risk of bipolar disorder - 267 of which were newly discovered in the current version of GWAS. The study also identified a new region that is associated with an increased risk of bipolar disorder, particularly in samples of East Asian origin. In the identified regions, 36 specific genes are suspected to be relevant for bipolar disorder. The next steps in research could be to investigate these genes in more detail. They could also be used to research new targets for drugs against bipolar disorder.

“In the study, we also found genetic differences between different clinical manifestations of bipolar disorder. This may be important for research into new diagnostic and treatment approaches,” says Prof. Dr. Markus Nöthen, Director of the Institute of Human Genetics at the UKB and co-author of the study. He is a member of the Cluster of Excellence ImmunoSensation2 of the Transdisciplinary Research Area (TRA) “Life and Health” and at the University of Bonn.

“Our results also suggest that different types of nerve cells in the brain play a role in bipolar disorder, and possibly also certain cells outside the brain. This is where further research can start,” adds Friederike David, doctoral student at the University of Bonn's Institute of Human Genetics at the UKB and shared second author of the study.

Funding

The study was conducted by the Psychiatric Genomics Consortium (PGC), an international consortium of researchers investigating the genetics of mental illness. The PGC comprises over 800 researchers from more than 150 institutions in over 40 countries. In German-speaking countries, in addition to the UKB and the University of Bonn, the Central Institute of Mental Health in Mannheim, the University Hospital of Munich, the Department of Psychiatry and Psychotherapy at the University Hospital of Marburg, the Department of Mental Health at the University Hospital of Münster and the University Hospital of Basel were also involved.

The study was funded by the US National Institute of Mental Health, among others.

Publikation

Kevin S. O’Connell et al.: Genomics yields biological and phenotypic insights into bipolar disorder; Nature; DOI: https://doi.org/10.1038/s41586-024-08468-9

 

Contact

Prof. Dr. Markus M. Nöthen

Director of the Institut of Human Genetics

University Hospital Bonn

Phone +49 228 287-51100

E-mail: markus.noethen@uni-bonn.de

Related news

News Icon

News categories: Publication

Diets need more sustainability

There has been a rapid increase in cardiovascular and metabolic conditions in sub-Saharan Africa. What is the link between sustainable diets that are nutritious, environmentally friendly, economically affordable, and socioculturally acceptable, and cardiometabolic conditions? An international research team led by Prof. Dr. Ina Danquah, Hertz Chair for Innovation for Planetary Health and Director at Center for Development Research (ZEF) at University of Bonn, investigated this question among Ghanaian adults who live in various locations.
View entry
Prof. Christian Strassburg, Direktor der Klinik für Allgemeine Innere Medizin am UKB, mahnt: „Die Abnehmpille ist nicht einfach nur irgendein Spaßfaktor, um jetzt ein bisschen abzunehmen!“

News categories: Publication

Weight-Loss Pill Instead of Injection: Finally, an Easy Way to Lose Weight?

As of September 1, semaglutide will be available in Germany for the treatment of overweight and obesity in tablet form for the first time. The therapy, previously known primarily as a “weight-loss injection,” can now also be taken orally. The market launch is likely to attract considerable interest – but anyone considering treatment should be aware of one thing first: the tablet is not a way to lose a few kilos, but a prescription medication for the treatment of a chronic disease.
View entry
Prof. Matthias Geyer, - together with Prof. Robert P. Fisher from New York, provides an overview of the current state of research on the transcriptional regulation of cyclin-dependent kinases (CDKs) and the prospects for cancer treatment.

News categories: Publication

A Ray of Hope in the Fight Against Cancer

Cancer is the second leading cause of death in Germany. In the search for new therapeutic approaches that target the uncontrolled growth of tumor cells, a class of enzymes known as cyclin-dependent kinases (CDKs) has come into focus. This is because this family of enzymes plays a fundamental role in gene expression and cell division. An overview of the current state of research on the transcriptional regulation of CDKs and the prospects for cancer treatment was compiled by Prof. Matthias Geyer of the UKB in collaboration with Prof. Robert P. Fisher and has now been published.
View entry

Back to the news overview